March 8, 2019
About the Author: Bradley Merrill Thompson is a member of the firm at Epstein Becker & Green, P.C. There, he counsels medical device, drug, and combination product companies on a wide range of FDA regulatory, reimbursement, and clinical trial issues. The opinions in this piece are Thompson's and don't necessarily reflect the opinions of MobiHealthNews or HIMSS.
As a pro bono project, together...
March 20, 2017
New York-based healthcare technology company, Aetion, which makes an analytics platform to assess real-world evidence from a range of sources, has raised $11.2 million in Series A funding. Flare Capital Partners, a VC firm focused on early stage health technology and services, led the round, and Lakestar also contributed.
Aetion’s Evidence Platform, which the company launched in 2015, allows...
December 7, 2016
The 21st Century Cures Act has passed the Senate by a 94 to 5 vote, marking the last stop before President Obama’s desk to become a law.
As we reported before, The Cures Act took three years to pass and was one of the most hotly-lobbied healthcare bills in the current Congress. It passed in the House last week. The bill allocates $4.8 billion to the National Institutes of Health over the next 10...
November 29, 2016
The 21st Century Cures Act – a long-debated bill that would allocate extra funding to the National Institutes of Health as well as effectively speed up the FDA approval process for drugs and devices – is headed for a House vote this week.
The latest version of the bill, which was released over the holiday weekend, allocates $4.8 billion to the NIH over the next 10 years. The funding would go...